Standard treatment for hepatic encephalopathy (HE) includes medications that reduce ammonia and bacterial translocation in the gut. Rifaximin can be used off-label for the reduction of overt HE. The study purpose was to determine efficacy of traditional rifaximin dosing (400 mg three times daily) compared with newer dosing (550 mg twice daily) via readmission rates for the prevention of recurrent HE. This was a retrospective, observational, cross-sectional pilot study conducted in a tertiary medical center. A total of 226 patients 18-89 years of age with documentation of HE via ICD-9 code who started rifaximin therapy while inpatient between April 2009 and June 2014 were evaluated. Data collected included rifaximin dosing, other medications used to treat HE, duration of therapy, time to readmission, and various laboratory values. There were no differences in readmission rates at 30 days, 60 days, or 6 months between treatment groups. Additionally, there was no difference in the odds of readmission between the treatment groups (OR = 0.77, 95% CI: [0.201, 4.365], P = 0.718). Patients had a low overall probability of readmission over the observational period. Based on average wholesale price data, the cost for a 9-day supply of rifaximin for the 400-mg dosing regimen is $952.56 versus $605.16 for the 550-mg dosing regimen. The rifaximin 550-mg dosing strategy should be utilized in hospitalized patients for the prevention of recurrent HE as there was no difference in readmission rate or time to readmission between dosing groups. The 550-mg regimen had a lower acquisition cost for a 9-day duration of treatment in the studied institution.
Background
In the United States, an estimated 5.5 million patients are affected by liver cirrhosis, and approximately 50% of these patients are affected by hepatic encephalopathy (HE). [1] [2] [3] HE is a debilitating complication of liver cirrhosis defined as a neuropsychiatric syndrome with a spectrum of symptoms including mental status deterioration, psychomotor dysfunction, disorientation, and sensory abnormalities. 1 Hospitalization for episodic HE or occurrence of HE during hospitalization has been reported as high as 22,931 in 2009. HE leads to readmission rates of up to 69% in patients with decompensated cirrhosis, and of those recurrences, 80% occurred because of infection or gastrointestinal bleed. 3 Episodes of HE are associated with a poor prognosis; 42% 1-year survival rates and 23% 3-year survival rates have been reported. 4 Mortality from HE rises with increased frequency and severity of episodes and has been associated with decreased quality of life. 3, 5 The exact mechanism of HE is unknown, but there is an association with elevated serum ammonia levels. Although relevant, ammonia levels do not correlate with specific symptoms or severity, as inflammation can also impact levels. Medications that decrease ammonia, however, correlate with improvement in HE symptoms. 5 Elevated serum ammonia levels occur because of impaired metabolic activity in the liver, but the etiology of HE involves multiple organs including the kidney, muscle, brain, and gastrointestinal system. 6 Standard treatment for HE includes medications that reduce serum ammonia levels and bacterial translocation from the gut. 4, 5 Current clinical guidelines recommend first-line treatment with lactulose with the potential addition of other agents, such as rifaximin, if HE fails to be adequately controlled. 2 Rifaximin is a poorly absorbed rifamycin antibiotic that inhibits bacterial synthesis via binding to bacterial DNAdependent RNA polymerase. 7 Rifaximin's mechanism in the treatment and prevention of HE is unknown, but it is postulated that rifaximin decreases serum ammonia by reducing intestinal absorption and facilitating elimination. 5 In multiple clinical trials, rifaximin has been shown to be as or more effective than standard treatment with lactulose. 1, 8, 9 Rifaximin has subsequently received FDA approval for HE prophylaxis, in combination with lactulose, at a dose of 550 mg orally twice daily. This dosing regimen is different from other rifaximin indications, including traveler's diarrhea and the [unlabeled use] treatment of acute HE, which utilizes 400 mg taken orally three times daily. 6 There are no published studies evaluating the use of the 400 mg three times daily dosing regimen for the treatment of acute HE.
Materials and methods
This was a retrospective, observational, cross-sectional pilot study for which IRB approval was obtained. Patients ≥ 18 years of age with documented HE via ICD-9 code who received rifaximin while inpatient as a new medication between April 2009 and June 2014 were evaluated for inclusion. Patients who were pregnant, incarcerated, received rifaximin therapy before admission, and those receiving rifaximin for reasons other than HE were excluded. Patients with alcoholic hepatitis were not specifically excluded.
The primary endpoint was to determine efficacy of traditional rifaximin dosing (400 mg three times daily) compared with newer dosing (550 mg twice daily) via readmission rates for the prevention of recurrent HE. Information collected from electronic medical records included demographics, past medical history, receipt of other medications to treat HE both before and during admission, rifaximin order details, and relevant laboratory data. Time to readmission for HE, overall hospital length of stay, and cost considerations were also assessed. The model for end-stage liver disease (MELD) score was calculated for all patients, which predicts short-term mortality. 10 Continuous variables were summarized using the mean, standard deviation, median, minimum, maximum, and skew. Categorical variables were summarized using the percentage and count. The non-parametric Mann-Whitney U-test was used for continuous variables to test for a difference between the 400-and 550-mg rifaximin groups. The Fisher's exact test was used to compare the distribution of the 400-and 550-mg rifaximin groups for categorical variables. To assess the occurrence of readmission, binary logistic regression was used; Akaike information criterion stepwise model selection was used to identify the smallest set of regressors that were associated with the outcome. McFadden's adjusted pseudo R 2 was reported. We utilized the Kaplan-Meier curve, with Greenwood's standard error, to describe time to readmission because of HE and length of stay over the observation period. Confidence intervals were constructed using log-log transform. For comparing dose regimen Kaplan-Meier curves, we used the log-rank test (Mantel-Haenszel), to assess differences in the time to events. The proportional hazard regression model with Akaike information criterion stepwise model selection was used to assess adjusted relationships. The hazard ratio was reported for proportional hazards models; the standard error was reported using the exponential (hazard ratio) scale. All statistical tests performed were two-sided tests with an α-level of 0.05. All statistical analyses were performed using the R software environment for statistical computing and graphics (R Core Team 2014).
Results
A total of 226 patients were included in the study, 201 (88.94%) in the 550-mg group and 25 (11.06%) in the 400-mg group. Demographic and baseline clinical characteristics were comparable between groups (Table 1) . Mean age was 57 years (range 26-82 years), and approximately 60% were male. The majority of patients in each group had cirrhosis due to alcohol (68% in the 400-mg group and 43.7% in the 550-mg group) (Fig. 1) . Clinical characteristics were comparable between the groups ( Table 2 ). All patients had documented cirrhosis, but only 48% in the 400-mg group and 14% in the 550-mg group had a documented history of HE before the index admission. More patients in the 400-mg group received lactulose (P = 0.007) and/or metronidazole (P = 0.001) before admission. Also, more patients in the 400-mg group received metronidazole during hospitalization compared with the 550-mg group (P < 0.001).
Overall, 36 patients were readmitted during the studied time frame. Readmission at 30 days occurred in 3 (12%) of the 400-mg group and 19 (9.45%) of the 550-mg group (P = 0.718). Time to readmission varied greatly with a median of 29 days (range: 3-358 days). No significant differences were noted between rifaximin doses and time to readmission (Fig. 2) . Patients receiving hemodialysis during admission were readmitted for HE at a 4.2-fold higher rate than patients not receiving hemodialysis. Additionally, a 1-point increase in MELD score decreased the readmission rate from 11.5 to 10.4. The overall median length of stay was 9 days with a 6.6% chance of remaining inpatient for 30 days or more. Median length of stay was 8 days for the 400-mg group and 10 days for the 550-mg group, with no statistically significant difference noted (P = 0.613). Patients who did not receive lactulose during admission were discharged 2.2 times more quickly than patients who did receive lactulose. For every 5-unit increase in MELD score, the discharge rate increased by 15% (P = 0.005). No associations were found with either dosing regimen or odds of being readmitted at either 30 days or 6 months.
Of note, a 1-unit increase in MELD score resulted in a 7% decrease in the odds of being readmitted.
Discussion
Hepatic encephalopathy is a costly complication of liver cirrhosis and is estimated to cost more than $1.2 billion per year in the United States. 9 This retrospective study of rifaximin dosing for the prevention of acute HE found no major differences in readmission rates between the two dosing groups. Although the studied population varied greatly in total MELD score, the mean and median values were consistent with clinical cirrhosis. The median MELD score, 20 (range 3.81 to 51.05), correlates to an approximate 5% risk of mortality in the subsequent 3 months. 10 Cirrhosis and its complications yield high hospital readmission rates and increase the odds of unplanned readmission. One-month readmission rates for HE have been reported as high as 37%. 11, 12 Readmission rates for HE in this study population were 9.7% (n = 22) at 30 days and 16.1% (n = 36) at 6 months. This excluded the 37.6% of patients that died during the primary admission (12 [48%] in 400-mg group vs 73 [36.3%] in 550-mg group). There was no significant difference in readmission rates between groups at 30 days or 6 months. A clinically relevant trend may be noted as the 550-mg group had lower readmission rates compared with the 400-mg group at both 1 month (9.45% vs 12%) and 6 months (15.58% vs 20%), although the study was not powered to show significance. When the two arms were stratified among variables, a higher MELD score yielded a 7% reduction in the odds of being readmitted at 6 months. This may be due to increased risk of mortality and/or transition to end-of-life care in patients with higher MELD scores.
Time to readmission for HE may act as a marker of successful treatment, disease progression, and/or patient adherence to medication and lifestyle changes. 3 Of the patients readmitted HE, the median time was 29 days (range 3-358 days). No significant difference in time to readmission was noted between the dosing regimens at 30 days, 6 months, or 1 year. It was observed that patients receiving hemodialysis were readmitted for HE at a 4.2-fold higher rate. This increase in readmission correlates to the general hemodialysis population as they are admitted to the hospital on average two times per year with 30-day readmission rates as high as 36%. 13 It is important to note that a 1-point decrease in MELD score led to an 11% increase in the rate of readmission.
The mean length of stay in the study population (12.61 days) was greater in comparison with the general population (~4.5 days) and the Centers for Medicare and Medicaid Services population with cirrhosis (6.2 days).
14 In the study group, the chance of remaining in the hospital for 30 days or more was 6.6%, which is confounded by comorbidities and other reasons for hospitalization, none of which were specifically addressed. There was no significant difference between the 400-mg group and the 550-mg group in mean length of stay (11.04 vs 12.81 days, P = 0.991). Patients who did not receive lactulose during admission were discharged at a rate 2.2 times faster than those who received concomitant lactulose (P = 0.017). Lack of receipt of inpatient lactulose may have occurred because of various reasons, but there is no clear indication for rifaximin use as monotherapy for the prevention of , 400-mg rifaximin; , 550-mg rifaximin. [Color figure can be viewed at wileyonlinelibrary.com] recurrent HE. 2 The faster discharge rate may be related to the dosing of lactulose and the need to titrate to 2-3 loose stools per day. 2 In past studies, common preventable readmissions were noted in patients with lack of education on lactulose dosing or inappropriate use. 3 Additionally, with every 5-unit increase in MELD score, the discharge rate increased by 15%, which could be attributed to death or transition to end-of-life care after initial discharge.
Overall, increasing MELD scores were associated with reduced readmissions, time to readmission and length of stay. This observation is likely due to the near exponential increase in mortality with higher MELD scores. 10 The study design prevented the collection of outpatient data, preventing assessment of how many patients died after discharge, were transitioned to hospice or comfort care, or were readmitted to another facility.
The median inpatient rifaximin duration was 7 days (range 1-68 days); 8 days in the 400-mg group and 9.28 days in the 550-mg group (P = 0.97). The overall even distribution of pertinent variables aided in determining a difference between the two treatment groups. More patients in the 400-mg group received either lactulose or metronidazole therapy before admission. In addition, more patients in the 400-mg group received metronidazole therapy while inpatient. The use of multiple agents before admission in the older dosing regimen group may represent unfamiliarity with rifaximin as its use for HE was still relatively new at this time. Accordingly, the same reasoning may explain why more patients in the 400-mg group also received metronidazole for HE while inpatient.
Rifaximin (Xifaxan, Salix Pharmaceuticals, Ontario, Canada) is available as a brand-only medication. As with all medications, efforts to reduce cost are prudent to aid in optimized patient compliance. A recent study by Khokar and colleagues examined the potential utility of rifaximin dosed at 550 mg taken only once daily. 15 When comparing this regimen to the standard 550 mg twice daily regimen, they found no significant difference in their outcome of breakthrough episode of encephalopathy. 9 Other than using the current FDA-approved dose once daily, it was theorized that using the older dosing regimen of 400 mg by mouth three times daily may prove more costeffective. However, based on average wholesale price and our length of stay data, the cost for a 1-day supply of rifaximin for the 400-mg dose is $105.84 versus $67.24 for the 550-mg dose (Table 3) . 16 Additionally, the older dosing regimen requires patients to take two tablets three times daily (six total tablets daily), potentially limiting compliance.
There were limitations noted with the study. There was an overall low sample size (225 patients), with patient numbers especially restricted in the 400-mg group. Sample recruitment in the 400-mg group was limited by transition to a new electronic medical record system that did not contain a large number of complete medical records for this group. The retrospective nature of this study allowed for inconsistencies with available data for collection. This study did not assess patient comorbidities, a factor that may contribute to overall mortality and severity of cirrhosis and its complications. Retrospective data collection also did not allow for assessment of patient compliance and continuation or discontinuation of rifaximin regimens following discharge, which limits generalizability. Additionally, diagnosis of episodic versus persistent HE was not able to be assessed, which would have an effect on hospital length of stay data. Because of the large variation in overall length of stay, the MELD score was calculated for all patients based on initial laboratory values collected during admission, which may have over-estimated or under-estimated true severity. Finally, this study was conducted at a large tertiary care center; therefore, readmissions to other hospitals in the state not requiring tertiary level of care could not be determined.
Conclusion
In conclusion, the rifaximin 550-mg dosing strategy should continue to be utilized in hospitalized patients for the prevention of recurrent HE as there was no difference noted in readmission rate or time to readmission between the two dosing groups. Further studies should be conducted in larger sample sizes before the use of the rifaximin 400 mg by mouth three times daily regimen is recommended for use in the prevention of HE. 
